title: [Efficacy of docetaxel (TXT) combined with cisplatin (CDDP) in non-small cell lung cancer].
abstract: A multicenter cooperative study of docetaxel (60 mg/m2) combined with cisplatin (60 mg/m2) was performed in stage III and IV patients with inoperable non-small cell lung cancer from March 1998 to September 1999. Of 37 patients enrolled, 36 patients were eligible. One patient obtained a complete response (CR) and nine patients had a partial response (PR). The overall response rate in 36 patients was 28.6%. The median survival time was 360 days. The response rates of stage III and stage IV patients were 36.8% and 18.7%, respectively. The median survival times of stage III and stage IV patients were 502 days and 286 days, respectively. The major toxicities were grade 3 leukopenia (16.2%), grade 3 neutropenia (32.4%), and grade 4 neutropenia (10.8%).
authors.affiliation: Dept. of Internal Medicine, Saga Social Insurance Hospital.
authors.forename: Shigetaka
authors.initials: S
authors.lastname: Kuroki
authors.forename: Kentaro
authors.initials: K
authors.lastname: Iwanaga
authors.forename: Osamu
authors.initials: O
authors.lastname: Kato
authors.forename: Koichiro
authors.initials: K
authors.lastname: Takahashi
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Haruta
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Soejima
authors.forename: Koutarou
authors.initials: K
authors.lastname: Koyanagi
authors.forename: Tsugio
authors.initials: T
authors.lastname: Furukawa
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Soejima
authors.forename: Masaki
authors.initials: M
authors.lastname: Nagata
authors.forename: Keiko
authors.initials: K
authors.lastname: Naitoh
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Aoki
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Hayashi
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage; D000077143:Docetaxel; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000031:analogs & derivatives*; D015996:Survival Rate; D043823:Taxoids
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel; D002945:Cisplatin